TransCode Therapeutics has launched a formal strategic process to explore options for its oncology portfolio, focusing on its lead RNA-based therapeutic candidate, TTX-MC138, now in Phase 2a trials for ctDNA-positive colorectal cancer. The process may include licensing, partnerships, or asset sales to support development and maximize shareholder value. TTX-MC138 targets microRNA-10b to inhibit metastatic cancer progression and is being tested in collaboration with Quantum Leap Healthcare and Natera to improve patient enrollment. The company cautions that the process may not lead to a transaction and will update only if a specific outcome is approved.
TransCode Therapeutics' oncology portfolio is the subject, with Pluang's Health sector market data providing context. As of Oct 29, 2026 03:21 WIB, 103 of 150 priced Health-sector US stocks rose while 46 fell. Notable movers include Axogen Inc (AXGN) at USD 48.98 with a 30.75% increase and a Pluang order activity of 63% Buy, and Ginkgo Bioworks Holdings Inc (DNA) at USD 13.33, up 18.28%.
Fort Technology received a notification from Nasdaq on October 13, 2026, stating it failed to meet the minimum bid price requirement of $1.00 per share over the past 30 days. The company has 180 days, until April 12, 2027, to restore its share price ...
The global mobile battery market, valued at $24.9 billion in 2025, is projected to grow to $45.95 billion by 2035, driven by rising smartphone adoption, 5G rollout, and demand for longer-lasting, fast-charging batteries. Lithium-ion batteries dominat...
SpaceX reported a strong Q3 with revenue up 161% year-over-year to $14.6 billion and a net profit of $4.4 billion, reversing last year's loss. Starlink, its satellite internet service, grew revenue by nearly 70% to $5.2 billion and added 1.6 million ...
SPIE, a leading European multi-technical services provider, has signed an agreement to acquire a 76% stake in SAR ANLAGENBAU GmbH, a major electrical engineering and automation firm based in Austria and Germany. This acquisition will enhance SPIE's p...
SPIE, a European leader in energy and communication services, has agreed to acquire a 76% stake in SAR ANLAGENBAU GmbH, a key electrical engineering and automation firm in Austria and Germany. This acquisition will broaden SPIE's service portfolio in...
